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Using a combination of transplacental carcinogen exposure
and retrovirus-mediated oncogene transfer into fetal brain
transplants, we have studied complementary transformation
by N-ethyl-A'-nitrosourea (NEU) and the \-myc oncogene in
the nervous system. Previous experiments had demonstrated
that both agents will not induce tumors independently whereas
simultaneous expression of v-H-ras and y-gag/myc exerted a
powerful transforming potential in neural grafts. In order
to identify other genetic alterations that co-operate with an
activated myc gene, the neurotropic carcinogen NEU was used
to generate mutations of cellular genes. On embryonic day
14 (ED14), pregnant donor animals (F344 rats) received a
single i.v. dose of NEU (50 mg/kg). Twenty-four hours later
(ED15), the fetal brains were removed, triturated and
incubated with a retroviral vector carrying the y-gag/myc
oncogene. Subsequently, these primary cell suspensions were
transplanted stereotactically into the caudate-putamen of
syngenic adult recipients. After latency periods of 3 - 6
months, 5 of 10 recipients harboring ED15 fetal brain
transplants developed malignant, poorly differentiated
neuroectodennal tumors in the grafts. No tumor development
was observed in seven recipients harboring ED16 neural
grafts. Cell lines were established from three tumors and the
110 kd gag/myc fusion protein encoded by the retroviral
construct was identified in the tumors by Western blotting.
Several candidate genes for mutational activation by NEU
including the H-ras, K-ras and neu oncogenes were analyzed
for specific point mutations by polymerase chain reaction
(PCR) and direct DNA sequencing of the PCR products.
However, no mutations were found in any of these genes.
These findings lend further support to the multistep
hypothesis of neoplastic transformation in the brain. The
tumors induced in this model provide an interesting tool for
the identification of genes that co-operate with an activated
myc gene in neurocarcinogenesis.
We have recently established a novel strategy to introduce foreign
genes into the central nervous system. This approach employs
retrovirus-mediated gene transfer into neural and non-
neuroectodermal cells of fetal brain transplants (1-3) . In this
•Abbreviations: NEU, A*-ethyl-Mnitrosourea; IMDM, Iscove's modified Dulbec-
co's medium; ED, embryonic day; H - E , hematoxylin-eosin; GFAP, glial
fibrillary acidic protein; NSE, neurone-specific enolase; PCR, polymerase chain
reaction.
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model, the simultaneous expression of activated ras and myc
genes yields highly malignant neoplasms in 100% of the grafts.
Introduction of a retroviral construct containing the v-myc gene
only or pretreatment of the donor cells with a single prenatal dose
of the neurotropic carcinogen Af-emyl-Af-nitrosourea (NEU*) does
not result in a malignant phenotype (3,4). Since to date no
mutationally activated ras genes have been detected in sporadic
human brain tumors, the combination of ras and myc genes does
not appear to play a role in human neurocarcinogenesis. In
contrast, the myc oncogene family has been associated with the
pathogenesis of a variety of neuroectodermal tumors (5,6). In
order to identify other genes that co-operate with myc in neoplastic
transformation, we have combined the expression of an activated
myc gene with a second transforming agent, i.e. a single exposure
of the donor cells to the alkylating carcinogen NEU.
For gene transfer into neural grafts, the replication-defective
retroviral vector, DoK \-myc, which is based on the Moloney
sarcoma virus genome, was used (Figure 1). This retroviral
construct harbors the w-gag/myc gene of the MC29 avian
myelccytomatosis virus and a bacterial phosphoribosyl transferase
gene (jieoT) (7). Retroviral particles were produced in the \p2
helper-free packaging cell line (8). \}/2 cells were kept in Iscove's
modified Dulbecco's medium (IMDM) containing 10% newborn
calf serum and virus containing supernatant was collected
overnight at - 8 0 % confluency.
Fetal CNS donor cells were prepared as described (1,9).
Briefly, timed Fischer (F344) rats received a single i.v. dose of
NEU (10 mg/ml in 3 mM sodium citrate, pH 5.6; total dose:
50 mg/kg) at days 14 or 15 of gestation. Twenty-four hours later,
i.e. on embryonic day (ED) 15 or 16, the embryos were removed
and the entire fetal brain was carefully dissected. Approximately
10 fetal brains were enzymatically dissociated (0.25% trypsin,
0.1% DNase in PBS, 10 min at room temperature) and gently
triturated in order to obtain a single cell suspension. For retroviral
infection the cells were incubated with the tissue culture
supernatant of the \p2 packaging cell line in the presence of
polybrene (3 /tg/ml) for 4 h at 37°C and 5% CCV After
adsorption of the virus, the cells were washed with Hank's
balanced salt solution to remove free retroviral particles. Cells
were then pelleted and immediately used for transplantation. Host
animals (adult male F344 rats, body wt 150—200 g) were
anesthetized with 0.2 mg fentanyl and 10 mg droperidol/kg body
wt and received a single stereotaxic injection of 5 /U cell suspen-
sion containing ~ l(r cells into the center of the left caudate-
putamen. Control neural grafts with fetal donor cells exposed
only to a transplacental dose of NEU or to the retroviral vector
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Fig. 1. Structure of the retroviral vector harboring cDNAs for the v-
gag/myc gene of the MC29 avian myelocytomatosis virus and the
Escherichia coli phosphoribosyl transferase gene {ne<f). Expression of the v-
gag/myc gene is driven by the Moloney murirte leukemia virus 5' long
terminal repeat.
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encxxling \-gag/myc did not develop any pathology within an
observation period of 12 months.
Postoperatively, recipient animals were closely monitored for
signs of neurological impairment. Animals with severe
neurological symptoms were anesthetized with diethyl ether and
decapitated. Frontal brain slices were fixed in 4% buffered
paraformaldehyde (pH 7.6) and embedded in paraffin. Sections
from all animals were stained with hematoxylin—eosin (H-E).
For immunocytochemical reactions, polyclonal antibodies to glial
fibrillary acidic protein (GFAP; Dakopatts, Copenhagen,
Denmark), neurone-specific enolase (NSE; Dakopatts), S-100
protein (Dakopatts), and monoclonal antibodies to synaptophysin
Fig. 2. Microscopic appearance of neural transplants exposed to NEU and
the v-gag/myc gene. (A) Control transplant with a prominent population of
mature neurones and glia. Note the focal pseudocortical arrangement of
neuronal cells ( H - E , x250). (B) Solid tumor (arrow) in a transplant 3
months after exposure of the donor cells to NEU and a retroviral vector
encoding the v-gag/myc gene. Note the infiltration of the tumor cells into
the adjacent subarachnoid space (arrowheads). Unaffected graft tissue
(asterisk) is located beneath the tumor ( H - E , Xl5). (C) At higher
magnification, the undifferentiated tumor cells exhibit prominent nuclei and
a small rim of eosinophilic cytoplasm. Numerous mitotic figures and areas
of necrosis indicate malignancy ( H - E , X330).
(SY-38, Boehringer, Mannheim, Germany), neurofilament
protein (Becton Dickinson), vimentin (Dakopatts) and the
panepithelial antigen Lu-5 (F.Hoffmann-La Roche, Basel,
Switzerland) were used. Polyclonal antibodies were visualized
with a commercial avidin-biotin—peroxidase kit (Dakopatts),
monoclonal antibodies with a peroxidase-anti-peroxidase
reaction.
Aliquots of tumor tissue were established as cell cultures and
grown in IMDM containing 10% fetal calf serum. Starting 7 days
after primary seeding, the cultures were propagated in selection
medium containing geneticin (GIBCO, 0.8 mg/ml). In vitro
differentiation of geneticin-resistant colonies derived from this
experiment was assessed morphologically and immunocyto-
chemically. In order to investigate the differentiation capacity
of the established cultures in vivo, tumor cell lines were
retransplanted into the brain of adult recipient animals as
described above.
For Western blot analysis of the established tumor cell lines,
cells were washed in cold PBS and incubated in lysis buffer
(0.05 M NaCl, 50 /*M leupeptin, 0.5% Nonidet P-40, 0.5%
SDS, 0.5% sodium deoxycholate in 20 mM Tris-Cl, pH 7.4)
for 15 min at 4°C. The suspensions were sonicated for 20 s and
subsequently pelleted at 12 000 g, 4°C for 30 min. Each sample
(10 mg) was separated on a 7.5% polyacrylamide gel and
transferred to a nitrocellulose membrane. A polyclonal rabbit
antibody to the bacterially expressed exon 3 of the v-myc gene
(Medac, Hamburg, Germany; dilution 1:500) and an immunoblot
alkaline phosphatase assay kit (Bio-Rad Laboratories, Richmond,
CA) were used to visualize the myc proteins.
Polymerase chain reaction (PCR)-mediated DNA amplification
from paraffin sections and Sanger dideoxynucleotide sequencing
of the PCR products were performed as described (10). Primer
oligonucleotides for PCR were 5'-GCCTGCTGAAAATGAC-
TGAG and 5'-CTCTATCGTAGGATCATATTC for exon 1 of
K-ras, 5'-GACTCCTACAGGAAACAAGT and 5'-AGAAA-
GCCCTCCCCAGTTCT for exon 2 of K-ras, 5'-TCATTGGCA-
GGTGGGGCAGGA and 5'-GAGCTCACCTCTATAGTGGGA
for exon 1 of K-ras, 5'-GACTCCTACCGGAAACAGGT and
5'-CTGTACTGATGGATGTCTTC for exon 2 of H-ras, and
5'-CAGCCCGGTGACATTCATCA and 5'-TCGTATACTTC-
CGGATCTTCTGTCT for the neu gene. Sequencing primers
were 5'-TCTGAATTAGCTGTATCGTC for exon 1 of K-ras,
5'-GTAATTGATGGAGAAACCTG for exon 2 of the K-ras,
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Fig. 3. Western blot analysis with an antibody to the bacterially expressed
exon 3 of the v-myc gene. The 110 kd gag/myc fusion protein is detectable
in the three cell lines derived from tumors induced in fetal neural grafts
after exposure to NEU and v-gag/myc (951, 758, 759). Note the inverse
correlation between the levels of v-gag/myc (upper band, 110 kd) and c-myc
proteins (lower bands). C, Mock-infected fetal brain cells (negative control).
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5'-ACCCCTGTAGAAGCGATGAC for exon 1 of H-ras,
5'-GTCATTGATGGGGAGACGTG for exon 2 of H-ras and
5'-TCGTATACTTCCGGATCTTCTGTCT for the neu gene.
The animals harboring ED 16 transplants were killed after a
survival period of 9 months without any signs of neurological
impairment. All seven recipients exhibited regular grafts with
the characteristic histological appearance of embryonal brain
transplants, i.e. an irregular distribution of neurones and glial
elements and formation of pseudocortical architectures (Figure
2A). Immunohistochemically, NSE, synaptophysin and neuro-
filament protein were readily detectable in neurones of the graft.
Astrocytes were identified with antibodies to GFAP. No evidence
for an abnormal phenotype or tumor formation was noted in these
transplants. In contrast, 5 of 10 recipient animals carrying ED15
transplants developed severe neurological symptoms 3 - 6 months
after grafting. Post-mortem examination showed highly malignant
tumors originating from the graft in all five animals (Figure 2B
and Q . The tumor cells exhibited round to oval nuclei and a
small rim of eosinophilic cytoplasm. Histopathological criteria
for malignancy included numerous mitotic figures and focal
necroses. Metastatic spread along the CSF into the cerebral
ventricles and the subarachnoid space was noted in three
recipients. Immunohistochemical analysis of the neoplasms
revealed no expression of GFAP, synaptophysin and
neurofilaments, i.e. antigens that indicate advanced glial or
neuronal differentiation. The tumor cells showed no immuno-
reactivity for epithelial or mesenchymal antigens, i.e. the
panepithelial antigen Lu-5 and vimentin. In all five animals,
remnants of unaltered graft tissue were found adjacent to the
neoplasms (Figure 2B).
Geneticin-resistant permanent cell lines were obtained from
three tumor specimens. In culture, the tumor cells exhibited round
to oval nuclei and a small rim of cytoplasm that frequently
extended into short bipolar processes. In contrast to the primary
tumors, the cell lines showed a weak expression of NSE and
S-100 protein. Expression of the retrovirally encoded myc protein
was confirmed by Western blot analysis. The 110 kd gag/myc
fusion protein was readily detectable in extracts of the cell cultures
but was absent in the spent media and in protein extracts
respectively from cultured fetal brain cells not exposed to the
retrovirus. The antibody showed cross-reactivity with endogenous
c-myc products. An inverse correlation between c-myc expres-
sion and expression of the introduced v-gag/myc gene was noted
(Figure 3). Intracerebral retransplantation of the tumor cell lines
into adult recipient animals yielded rapidly growing neoplasms
within 2 weeks of transplantation. These tumors showed
histopathological features indistinguishable from the primary
tumors. Immunohistochemically, there was no evidence for
advanced glial or neuronal differentiation.
DNA sequence analysis of the neu transmembrane region
revealed wild-type sequences in all five tumor specimens. No
alterations were detected in codon 659, which is consistently
mutated in NEU-induced schwannomas of the peripheral nervous
system (11). Sequence analysis of exons 1 and 2 of the H- and
K-ras genes showed no abnormalities within the mutational hot
spots, i.e. codons 12, 13 and 61. Therefore, it is unlikely that
neoplastic transformation is due to complementation with an
activated ras gene.
Our findings indicate that NEU has the potential to mutationally
activate or inactivate cellular transforming genes, which can co-
operate with myc in neurocarcinogenesis. However, the respective
target genes of NEU remain unknown. Attempts to identify by
transfection assay a transforming gene involved in the induction
of CNS gliomas by NEU have failed (11). This might indicate
that NEU-induced carcinogenesis is mediated via a recessive
mechanism, e.g. inactivation of a tumor suppressor gene.
Mutational inactivation of the p53 tumor suppressor gene has been
implicated in the pathogenesis of several neuroectodermal tumors
(12-14). Recently, a high incidence of p53 mutations was found
in rat nephroblastomas induced by transplacental exposure to
NEU (15). Preliminary results suggest that the neoplasms induced
in neural transplants exposed to NEU and the v-gag/myc gene
do not carry p53 mutations (unpublished data).
Interestingly, tumorigenesis was restricted to ED15 grafts; no
neoplastic lesions were noted in transplants derived from ED 16
and ED14 (data not shown) donor cells. This indicates that the
susceptibility of the respective target cell population to the
transforming effect of NEU and an activated myc gene is
restricted to a specific developmental stage. The fact that
integration of retroviral vectors into the host genome declines
significantly after ED 14 (unpublished data) may further support
such a temporal restriction.
The absence of preneoplastic lesions within the transplants and
the considerable latency periods between transplantation and
tumorigenesis suggest that combined exposure to NEU and v-
gag/myc initiates neoplastic transformation in the donor cells but
is not sufficient to produce a malignant or premalignant
phenotype. Acquisition by these initiated cells of yet additional
genetic alterations appears to be necessary for tumor formation.
In conclusion, our results provide in vivo evidence for a
multistep development of brain tumors. Expression of the v-
gag/myc gene in fetal brain transplants previously exposed to
NEU represents an approach for identifying cellular genes that
co-operate with activated myc in neurocarcinogenesis.
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